Pre-Exposure Prophylaxis PrEP
Pre-Exposure Prophylaxis PrEP Pre-Exposure Prophylaxis PrEP
Preferred regimenARV regimens forHIV occupational PEPTenofovir/emtricitabine (Truvada) plus raltegravir (Isentress)Alternative regimensTenofovir/emtricitabine (Truvada) plus ritonavir-boosted atazanavir(Reyataz)Tenofovir/emtricitabine (Truvada) plus ritonavir-boosted darunavir(Prezista)Additional possible regimensEfavirenz/tenofovir/emtricitabine (Atripla)Tenofovir/emtricitabine (Truvada) plus lopinavir/ritonavir (Kaletra)These are recommendations of the authors and are consistent with the 2012 United States DHHS guidelines fortreatment of HIV-infected adults. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the useof Stavudine antiretroviral agents and in HIV-1 lamivudine infected adults in and place adolescents. of tenofovir/emtricitabine Department Health and Human Services. if 1-239.Available at http://www.aidsinfo.nih.gov.cuml1.md.chula.ac.th/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. contraindicatedAccessed 28 March 2012.Bartlett JG. Management of healthcare personnel exposed to HIV. UpToDate. July 2012http://www.uptodate.com/home/clinicians/index.html
- Page 3 and 4: THAILANDAdult (15-49 years) HIV Pre
- Page 5 and 6: December 2009
- Page 7 and 8: ้วิธีการต่า
- Page 9 and 10: ่่้การใช้ยา
- Page 11 and 12: • The ongoing use of one or two a
- Page 14: Miller CJ, et al. J Virology 2005 :
- Page 17 and 18: WhyTenofovirand/orEmtricitabine?
- Page 19 and 20: Tenofovir (Viread) for PrEP• Nucl
- Page 21 and 22: เพร็พแบบกินOr
- Page 23 and 24: ีื่การศึกษา
- Page 25 and 26: ความสัมพันธ
- Page 27 and 28: ความท้าทายอ
- Page 29 and 30: PrEP would be an addition to, not a
- Page 31 and 32: HIVPost-Exposure Prophylaxis (PEP)
- Page 33: Last updated Jan 21, 2005© World H
- Page 36 and 37: ความเสี่ยงใ
- Page 38 and 39: Definitely Potentially Not infectio
- Page 40 and 41: Risk of HIV Occupational Transmissi
- Page 42 and 43: Estimated Pathogen‐Specific Seroc
- Page 44 and 45: Other Cofactors• Source HIV viral
- Page 46 and 47: 1. First aids2. Counseling & Assess
- Page 48 and 49: HIV PEP• Current multidrug regime
- Page 50 and 51: Indications for Occupational PEP*So
- Page 52 and 53: Recommended PEP RegimensBASIC REGIM
- Page 56 and 57: Follow-up of HCP exposed to known o
- Page 58 and 59: ื็แนวทางการ
- Page 60 and 61: ูุตารางที่ 2.1
- Page 62 and 63: Situations when nPEP is consideredB
- Page 64 and 65: Choices of ART for nPEP• Newer dr
- Page 67 and 68: ARV Regimens for HIV nPEPPreferred
- Page 69 and 70: Major Differences betweenNon-occasi
<strong>Pre</strong>ferred regimenARV regimens forHIV occupational PEPTenofovir/emtricitabine (Truvada) plus raltegravir (Isentress)Alternative regimensTenofovir/emtricitabine (Truvada) plus ritonavir-boosted atazanavir(Reyataz)Tenofovir/emtricitabine (Truvada) plus ritonavir-boosted darunavir(<strong>Pre</strong>zista)Additional possible regimensEfavirenz/tenofovir/emtricitabine (Atripla)Tenofovir/emtricitabine (Truvada) plus lopinavir/ritonavir (Kaletra)These are recommendations of the authors and are consistent with the 2012 United States DHHS guidelines fortreatment of HIV-infected adults. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the useof Stavudine antiretroviral agents and in HIV-1 lamivudine infected adults in and place adolescents. of tenofovir/emtricitabine Department Health and Human Services. if 1-239.Available at http://www.aidsinfo.nih.gov.cuml1.md.chula.ac.th/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. contraindicatedAccessed 28 March 2012.Bartlett JG. Management of healthcare personnel exposed to HIV. UpToDate. July 2012http://www.uptodate.com/home/clinicians/index.html
Change language